3P Biopharmaceuticals is a leading European CDMO specialized in the process development and GMP manufacturing of biologics and cell therapy products. 3P offers its customers solutions at all stages of bio drug development: from initial research, preclinical and clinical phases to commercial phases. Its extensive experience in projects covering all stages of the process development and manufacturing in three different expression systems (mammalian, bacterial and yeasts), its flexibility and adaptation with its innovative technology and its vast human capital have made it a reference for the European market. Its notable technical successes have led it to manufacture over 50 molecules for over 30 customers from countries such as Norway, France, the United Kingdom, Germany, Switzerland, Belgium, Australia and the United States.
In 2017, 3P Biopharmaceuticals is celebrating its 10th Anniversary in a context of international success. In just 10 years, it has managed to build a first-tier facility with a quality system in line with European and US regulations. 3P has a highly qualified staff – 57% of its more than 150 employees hold doctorate and/or master’s degree in areas such as chemical sciences, pharmacy or engineering.